Recent Quotes (30 days)

You have no recent quotes
chg | %

Cascadian Therapeutics Inc (USA) news

   Watch this stock
Showing stories 1 - 10 of about 86   

Articles published

CASC 3.65 -0.04 (-1.08%)
price chart
Cascadian Therapeutics Added to the Nasdaq Biotechnology Index
SEATTLE, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (Nasdaq:CASC), a clinical-stage biopharmaceutical company, today announced that it has been selected for addition to the Nasdaq Biotechnology Index� (Nasdaq:NBI), which will become ...
Nea Management Company, Llc is the biggest holder of Cascadian Therapeutics ...  Post Analyst
Cascadian Therapeutics (CASC) Earns Coverage Optimism Score of 0.12  The Ledger Gazette
Cascadian Therapeutics: Upside In Other Her2+ Indications
Shares have finished flat since my initial piece on the company, but I still believe the stock could do well in the medium term.
Cascadian Therapeutics Announces Changes to Board of Directors
SEATTLE, March 13, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Robert W. Azelby has been appointed to the Company's Board of Directors. Mr. Azelby is a ...
Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress
In December 2016, Cascadian announced that following a recent meeting with the U.S. Food and Drug Administration (FDA) it has amended the HER2CLIMB Phase 2 clinical trial of its investigational product, tucatinib, by increasing the sample size so that ...
Cascadian Therapeutics Reports Third Quarter 2017 Financial Results
SEATTLE, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2017, and provided an update on tucatinib, an ...
Cascadian Therapeutics' (CASC) CEO Scott Myers on Q3 2017 Results ...  Seeking Alpha
Cascadian Therapeutics to Report Second Quarter 2017 Financial Results on ...
SEATTLE, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter financial results after the close of the U.S. financial markets on ...
Cascadian Therapeutics (CASC): Positive Momentum for Metastatic Breast ...  Equities.com
Cascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in ...
SEATTLE, July 11, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced the outcome of discussions with the European Medicines Agency (EMA) regarding the development of ...
Cascadian Therapeutics' Lead Candidate, Tucatinib, Receives Orphan Drug ...
Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer.
Cascadian Therapeutics' (CASC) CEO Scott Myers On Q2 2017 Results - Earnings ...
The press release referring our financial results was issued following the close of the US market and is available on our website, cadcadianrx.
Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted to ...
... people in the United States. Orphan designation qualifies the sponsor of the drug for certain development incentives, including tax credits for qualified clinical testing, prescription drug user fee exemption and 7-year marketing exclusivity upon ...
25 Stocks Moving In Wednesday's Pre-Market Session  Benzinga